Liu Jingzhen introduced that on February 1, Sinopharm group, as the leading unit, won the urgent approval of the key special inactivated vaccine project of public security risk prevention and control and emergency technical equipment of the national key R & D plan of the Ministry of science and technology. On April 12, the new crown inactivated vaccine developed by Wuhan Institute of biological products obtained the approval of clinical trial, and carried out domestic phase I / II clinical trial simultaneously. On April 27, the new crown inactivated vaccine developed by Beijing Institute of biological products was approved for clinical trial again, adding double insurance for the development of new crown vaccine. In the domestic phase I / II clinical study, a total of 4064 people in each age group were included in the study. The results of blinding revealed that the vaccine had good safety, and the high titer immune response was produced after vaccination with different ages, different procedures and different doses. After two doses of two vaccines were inoculated according to the 0 and 28 day program, the positive conversion rate of neutralizing antibody reached 100%.
Liu Jingzhen pointed out that at present, the new crown inactivated vaccine is in the full sprint stage, and Sinopharm groups research and development of biological vaccine in China is the last kilometer of a long march. After the safety and protection data of phase III clinical trial are obtained, the vaccine can be put on the market after being approved. In fact, emergency use has now begun. The two inactivated vaccines of sinopharma group and SINOCHEM are included in the scope of emergency use. At present, China biology has made preparations for large-scale production. Two production plants of new crown vaccine P3, namely Beijing Institute of biological products and Wuhan Institute of biological products, have been completed. The production capacity will reach more than 1 billion doses next year, which can ensure the safe and sufficient vaccine supply.